We found that CD133, CD54, CD44 and CD26 is stably expressed in circulating cancer cells of the peripheral blood using FACS analysis and that the CD133+cellular subpopulation could be used as the baseline to select CTCs in patients with CRC due to its high expression. This evidence concerns the gene DPP4 and cancer.